科华生物
(002022)
| 流通市值：34.30亿 | | | 总市值：34.30亿 |
| 流通股本：5.14亿 | | | 总股本：5.14亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 871,631,162.41 | 1,472,262,633.27 | 1,397,379,802.7 | 1,630,897,436.94 |
| 应收票据及应收账款 | 1,077,755,354.68 | 1,122,423,143.26 | 1,115,272,361.66 | 1,103,810,772.73 |
| 其中：应收票据 | 368,733.04 | 2,222,980 | 1,540,119.2 | 1,570,119.2 |
| 应收账款 | 1,077,386,621.64 | 1,120,200,163.26 | 1,113,732,242.46 | 1,102,240,653.53 |
| 应收款项融资 | 5,167,650.14 | 21,282,676.74 | 37,877,162.06 | 35,395,536.56 |
| 预付款项 | 160,057,719.52 | 125,689,155.53 | 145,385,957.08 | 126,841,472.51 |
| 其他应收款合计 | 21,238,080.72 | 24,731,859.52 | 24,804,935.44 | 24,167,288.24 |
| 存货 | 1,046,522,791.27 | 1,018,903,608.73 | 1,013,049,209.61 | 975,434,313.49 |
| 其他流动资产 | 108,905,036.01 | 102,122,509.2 | 104,957,999.32 | 102,931,061.08 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,443,996,206.91 | 4,089,772,747.06 | 4,142,000,005.65 | 4,316,244,225.33 |
| 非流动资产: | | | | |
| 长期应收款 | 27,607,886.42 | 26,591,387.13 | 22,544,625.41 | 25,728,689.39 |
| 长期股权投资 | 1,750,000 | - | - | - |
| 其他权益工具投资 | 24,886,900 | 24,886,900 | 24,886,900 | 24,886,900 |
| 投资性房地产 | 580,459.95 | 584,905.19 | 402,921.52 | 593,794.59 |
| 固定资产 | 853,741,820.28 | 865,256,831.75 | 834,169,591.09 | 839,009,544.48 |
| 在建工程 | 4,143,303.46 | 3,776,520.75 | 37,400,655.74 | 38,302,824.41 |
| 使用权资产 | 50,807,630.1 | 50,526,034.81 | 55,840,343.25 | 62,574,333.53 |
| 无形资产 | 414,264,806.86 | 393,676,047.35 | 387,700,985.31 | 387,840,151.39 |
| 开发支出 | 136,714,287.25 | 151,854,778.62 | 135,821,767.39 | 135,244,453.9 |
| 商誉 | 694,307,033.83 | 690,362,472.22 | 690,716,287.45 | 695,083,992.93 |
| 长期待摊费用 | 40,222,186.96 | 40,567,966.97 | 44,673,882.7 | 45,022,165.94 |
| 递延所得税资产 | 239,842,769.26 | 239,092,750.28 | 231,638,239.82 | 225,042,473.3 |
| 其他非流动资产 | 7,732,036.31 | 7,007,534.86 | 12,337,018.15 | 12,166,317.15 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,496,601,120.68 | 2,494,184,129.93 | 2,478,133,217.83 | 2,491,495,641.01 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,940,597,327.59 | 6,583,956,876.99 | 6,620,133,223.48 | 6,807,739,866.34 |
| 流动负债: | | | | |
| 短期借款 | 37,312,876.96 | 63,059,386.31 | 48,648,430.9 | 45,054,747.54 |
| 应付票据及应付账款 | 336,668,231.59 | 350,354,925.59 | 347,864,029.37 | 348,078,839.47 |
| 其中：应付票据 | 22,509,936.32 | 60,258,760.32 | 46,216,146.28 | 15,937,456.25 |
| 应付账款 | 314,158,295.27 | 290,096,165.27 | 301,647,883.09 | 332,141,383.22 |
| 合同负债 | 79,577,927.7 | 71,285,979.81 | 61,322,306.99 | 80,438,212.92 |
| 应付职工薪酬 | 58,427,472.47 | 53,972,429.12 | 59,577,452.57 | 126,813,714.47 |
| 应交税费 | 24,457,355.73 | 14,092,732.95 | 24,898,782.78 | 25,362,989.13 |
| 其他应付款合计 | 154,661,226.69 | 207,372,079.12 | 211,426,333.21 | 208,163,846.83 |
| 其中:应付利息 | 601,631.9 | 8,215,906.67 | 6,010,473.11 | 3,806,627.68 |
| 应付股利 | 82,797,150 | 120,797,150 | 115,697,150 | 115,697,150 |
| 一年内到期的非流动负债 | 57,665,002.3 | 58,053,884.1 | 57,936,137.44 | 60,447,088.44 |
| 其他流动负债 | 8,542,896.6 | 7,358,694.65 | 5,725,698.02 | 8,558,732.28 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 757,312,990.04 | 825,550,111.65 | 817,399,171.28 | 902,918,171.08 |
| 非流动负债: | | | | |
| 长期借款 | 98,777,546.47 | 94,810,275.61 | 88,953,716.53 | 91,979,472.41 |
| 应付债券 | 212,274,622.2 | 688,123,781.84 | 681,198,586.91 | 674,648,581.44 |
| 租赁负债 | 27,332,053.89 | 27,123,223.95 | 31,266,045.81 | 35,328,996.55 |
| 预计负债 | 45,813,055.51 | 48,054,884.44 | 60,362,016.28 | 60,165,296.89 |
| 递延收益 | 33,946,527.44 | 35,884,448.9 | 37,896,326.12 | 38,212,355.36 |
| 递延所得税负债 | 18,321,583.6 | 18,403,168.48 | 19,059,852.36 | 20,263,066.52 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 436,465,389.11 | 912,399,783.22 | 918,736,544.01 | 920,597,769.17 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,193,778,379.15 | 1,737,949,894.87 | 1,736,135,715.29 | 1,823,515,940.25 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 514,317,484 | 514,317,273 | 514,317,177 | 514,302,062 |
| 其他权益工具 | 43,515,441.18 | 142,426,796.4 | 142,427,182.82 | 142,487,463.6 |
| 资本公积 | 262,462,860.65 | 193,165,463.13 | 193,205,898.47 | 192,873,731.7 |
| 减:库存股 | 94,231,579.14 | 84,263,100.75 | 69,778,692.16 | - |
| 其他综合收益 | 9,328,090.02 | 2,929,225.66 | 3,461,003.46 | 10,787,718.87 |
| 盈余公积 | 228,578,647.53 | 228,578,647.53 | 228,578,647.53 | 228,578,647.53 |
| 未分配利润 | 2,960,946,443.57 | 3,030,622,997.21 | 3,054,265,646.78 | 3,083,087,100.9 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,924,917,387.81 | 4,027,777,302.18 | 4,066,476,863.9 | 4,172,116,724.6 |
| 少数股东权益 | 821,901,560.63 | 818,229,679.94 | 817,520,644.29 | 812,107,201.49 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 4,746,818,948.44 | 4,846,006,982.12 | 4,883,997,508.19 | 4,984,223,926.09 |
| 负债和股东权益合计 | 5,940,597,327.59 | 6,583,956,876.99 | 6,620,133,223.48 | 6,807,739,866.34 |
| 公告日期 | 2024-10-22 | 2024-08-30 | 2024-04-29 | 2024-03-23 |
| 审计意见(境内) | | | | 标准无保留意见 |